Novartis/HGS’ Albuferon May Offer Dosing Advantages Over Roche’s Pegasys
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III program for the chronic hepatitis C treatment includes two non-inferiority trials comparing once-weekly Pegasys to bi-weekly Albuferon.
You may also be interested in...
Novartis/Human Genome Sciences Launch Second Phase III Albuferon Trial
Firms plan 2009 regulatory filings for the hepatitis C treatment.
Novartis/Human Genome Sciences Launch Second Phase III Albuferon Trial
Firms plan 2009 regulatory filings for the hepatitis C treatment.
Gilead/Achillion Advance Back-Up Anti-HCV Molecule After Toxicity Problems With Lead Candidate
Companies plan IND filing for their next novel NS4A antagonist in the first or second quarter of 2008.